AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Talphera has secured up to $29 million in a private placement led by CorMedix. The financing includes $17 million upfront and $12 million contingent on meeting certain conditions. The funds will support the advancement of Talphera's programs, including Niyad, a regional anticoagulant for CRRT. The investment positions Talphera to be fully financed through a potential approval of Niyad, expected in the second half of next year.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet